Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis

Menopause

Volumn 16, Issue 6, 2009, Pages 1102-1108

  Pinkerton, Joann V ^a   Archer, David F ^b   Utian, Wulf H ^c   Menegoci, José C ^d   Levine, Amy B ^e   Chines, Arkadi A ^e   Constantine, Ginger D ^e  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Rapid Medical Research   (United States)

^c PONTIFÍCIA UNIVERSIDADE CATÓLICA DE SÃO PAULO   (Brazil)

^d PFIZER INC   (United States)

^e UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Bazedoxifene; Breast; Endometrium; Ovarian; Safety; Selective estrogen receptor modulator

Indexed keywords

BAZEDOXIFENE; CALCIUM; CALCIUM CARBONATE; RALOXIFENE;

ARTICLE; BONE DENSITY; BREAST CANCER; BREAST CARCINOMA; CANCER INCIDENCE; CLINICAL TRIAL; CONSENSUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMUR NECK; FIBROCYSTIC BREAST DISEASE; GENITAL SYSTEM; HISTOLOGY; HUMAN; LUMBAR SPINE; MASTALGIA; MULTICENTER STUDY; OSTEOPOROSIS; OVARY; OVARY CARCINOMA; OVARY CYST; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK; RISK FACTOR; SCORING SYSTEM; TRANSVAGINAL ECHOGRAPHY; TUMOR VOLUME; UTERINE CERVIX TUMOR; UTERUS BLEEDING; UTERUS MYOMA;

BONE DENSITY; BREAST; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; INDOLES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIAN CYSTS; OVARIAN NEOPLASMS; OVARY; PLACEBOS; POSTMENOPAUSE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 70350438889     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181a816be     Document Type: Article

References (22)

1. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004;94:256-266. (Pubitemid 39024525)
2. Lahti E, Blanco G, Kauppila A, Paja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-664. (Pubitemid 23137230)
3. Novo Nordisk drops levormeloxifene. SCRIP 1998;2374:18.
4. Smith Kline Beecham drops idoxifene for osteoporosis. SCRIP 1999; 2431:21.
5. Alexandersen. P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J Clin Endocrinol Metab 2001;86:755-760. (Pubitemid 32207492)
6. Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002; 187:521-527.
7. Fleischer AC, Wheeler JE, Yeh IT, Kravitz B, Jensen C, MacDonald B. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J Ultrasound Med 1999; 18:503-512. (Pubitemid 29291577)
8. Ravn P, Nielsen TF, Christiansen C. What can be learned from the levormeloxifene experience? Acta Obstet Gynecol Scand 2006; 85:135-142. (Pubitemid 43879232)
9. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 2001;949:317-326.
10. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008. (Pubitemid 41175771)
11. Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397-1404. (Pubitemid 40734275)
12. Miller PD, Chines AA, Christiansen. C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-535.
13. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral, fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and activecontrolled clinical trial. J Bone Miner Res 2008;23:1923-1934.
14. Miller CP, Harris HA, Komm BS. Bazedoxifene acetate. Drugs Future 2002;27:117-121.
15. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388. (Pubitemid 28439961)
16. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91:1654-1662. (Pubitemid 29479933)
17. Boss SM, Huster WJ, Neild JA, Giant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458-1464.
18. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.
19. Fugere P, Scheele WH, Shah A, Strack TR, Giant MD, Jolly E. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 2000;182:568-574. (Pubitemid 30207313)
20. Goldstein SR, Scheele WH, Rajagopalan. SK, Wilkie JL, Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000;95: 95-103.
21. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 2004;104:837-844. (Pubitemid 40458815)
22. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR.) P-2 trial. JAMA 2006;295:2727-2741. (Pubitemid 43920726)